Overview

This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients

Status:
Completed
Trial end date:
2019-10-24
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to understand the mechanism of action of BI655130 in patients with UC Secondary objectives are to explore clinical effect, safety and tolerability (including immunogenicity) of BI 655130 treatment
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim